Raltitrexed
Raltitrexed is an antimetabolite agent used in chemotherapy, acting by inhibiting thymidylate synthase.
Product Specifications
CAS Number
112887-68-0
Product Name Alternative
ZD1694; D1694; ICI-D1694
UNSPSC
12352005
Hazard Statement
H300, H360
Target
Nucleoside Antimetabolite/Analog; Thymidylate Synthase
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Raltitrexed.html
Concentration
10mM
Purity
99.51
Solubility
DMSO : ≥ 29 mg/mL
Smiles
CC(NC1=O)=NC2=C1C=C(CN(C)C3=CC=C(C(N[C@H](C(O)=O)CCC(O)=O)=O)S3)C=C2
Molecular Formula
C21H22N4O6S
Molecular Weight
458.49
Precautions
H300, H360
References & Citations
[1]Zhao H, et al. Raltitrexed Inhibits HepG2 Cell Proliferation via G0/G1 Cell Cycle Arrest. Oncol Res. 2016;23 (5) :237-48|[2]Dong Y, et al. Raltitrexed's effect on the development of neural tube defects in mice is associated with DNA damage, apoptosis, and proliferation. Mol Cell Biochem. 2015 Jan;398 (1-2) :223-31.|[3]Xue S, et al. Raltitrexed induces mitochondrial-mediated apoptosis in SGC7901 human gastric cancer cells. Mol Med Rep. 2014 Oct;10 (4) :1927-34.|[4]Waldman BC, et al. Induction of intrachromosomal homologous recombination in human cells by raltitrexed, an inhibitor of thymidylate synthase. DNA Repair (Amst) . 2008 Oct 1;7 (10) :1624-35.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K3985906 1.0 µg DNA
Tap2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1)
Sign In for Pricing
View Details 
abx505342 96 Tests
Human Coiled-coil domain-containing protein 19, mitochondrial (CFAP45) ELISA Kit
Sign In for Pricing
View Details